Cargando…
Trastuzumab in the management of early and advanced stage breast cancer
Trastuzumab is a monoclonal humanized antibody that has revolutionized the treatment of patients with Her2-positive breast cancer. Already well established in advanced stage disease, the substance was recently introduced in the adjuvant setting, reducing disease recurrences by more than 50% and mort...
Autores principales: | Bartsch, Rupert, Wenzel, Catharina, Steger, Guenther G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721347/ https://www.ncbi.nlm.nih.gov/pubmed/19707345 |
Ejemplares similares
-
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
por: Bartsch, Rupert, et al.
Publicado: (2006) -
Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2009) -
Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel
por: Bartsch, Rupert, et al.
Publicado: (2007) -
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
por: Petricevic, Branka, et al.
Publicado: (2013) -
Advances in the Management of Early-Stage Triple-Negative Breast Cancer
por: Bhardwaj, Prarthna V., et al.
Publicado: (2023)